This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. Primary support for the subproject and the subproject's principal investigator may have been provided by other sources, including other NIH sources. The Total Cost listed for the subproject likely represents the estimated amount of Center infrastructure utilized by the subproject, not direct funding provided by the NCRR grant to the subproject or subproject staff. The long term objective of our laboratory is to identify a key molecule that is sufficient to induce and sustain the phenotypes of normal epithelium in cancer cells. This project is innovative because it explores an intrinsic therapeutic pathway leading to the suppression of carcinoma progression through reestablishing normal phenotypes of epithelial cells. Dysfunctional epithelialization is characterized by loss of contact inhibition, gain of anchorage-independence, and inactivation of anoikis, a mode of cell death specifically induced after cell detachment from substratum. These phenotypes are all among the hallmarks of malignant carcinomas derived from transformed epithelial cells. We propose to test the hypothesis that BIN1, a nucleo-cytoplasmic adaptor protein that was identified originally as a c-MYC oncoprotein?interacting tumor suppressor, induces and sustains the epithelial-like phenotypes through inhibiting c-MYC. To test this hypothesis, we aim to 1) investigate whether c-MYC inhibition is necessary and sufficient for the BIN1-mediated epithelialization, 2) identify the BIN1 effectors that mediate contact inhibition and/or anoikis in malignant carcinoma cells, and 3) establish the upstream oncogenic pathways that enable the protection of carcinoma cells from BIN1-mediated epithelialization. To achieve the first aim, we will investigate the biological effects of activation and inactivation of the c-MYC oncoprotein on epithelial phenotypes in the presence of BIN1. To define the downstream signaling mechanism by which BIN1 sustains epithelial phenotypes in metastatic cancer cells, we will identify BIN1 effector molecules that are essential for mediating BIN1-dependent epithelialization. We previously reported that the abundance of BIN1 is significantly reduced or undetectable in malignant carcinoma cells. However, little or no human BIN1 gene deletion or translocation was evident in BIN1-deficient cancer cells, suggesting that oncogenic pressures might reduce the amounts of BIN1 mRNA or protein. Consistently, our preliminary results demonstrate that receptor-type tyrosine kinase oncoproteins, such as EGFR, negatively regulate BIN1 levels. Completion of this project will identify epithelium-associated BIN1 signaling pathways. This knowledge will be significant, as it may provide a unique therapeutic intervention by which metastatic potential of carcinoma cells may be eliminated by increasing BIN1 levels.

Agency
National Institute of Health (NIH)
Institute
National Center for Research Resources (NCRR)
Type
Exploratory Grants (P20)
Project #
5P20RR021970-07
Application #
8360461
Study Section
Special Emphasis Panel (ZRR1-CR-B (01))
Project Start
2011-07-01
Project End
2012-06-30
Budget Start
2011-07-01
Budget End
2012-06-30
Support Year
7
Fiscal Year
2011
Total Cost
$72,821
Indirect Cost
Name
Louisiana State Univ Hsc New Orleans
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
782627814
City
New Orleans
State
LA
Country
United States
Zip Code
70112
Rodriguez, Paulo C; Ochoa, Augusto C; Al-Khami, Amir A (2017) Arginine Metabolism in Myeloid Cells Shapes Innate and Adaptive Immunity. Front Immunol 8:93
Sanchez, Maria Dulfary; Ochoa, Augusto C; Foster, Timothy P (2016) Development and evaluation of a host-targeted antiviral that abrogates herpes simplex virus replication through modulation of arginine-associated metabolic pathways. Antiviral Res 132:13-25
Dai, Lu; Bai, Lihua; Lin, Zhen et al. (2016) Transcriptomic analysis of KSHV-infected primary oral fibroblasts: The role of interferon-induced genes in the latency of oncogenic virus. Oncotarget 7:47052-47060
Schieffelin, John; Moses, Lina M; Shaffer, Jeffrey et al. (2016) Clinical validation trial of a diagnostic for Ebola Zaire antigen detection: Design rationale and challenges to implementation. Clin Trials 13:66-72
Fletcher, Matthew; Ramirez, Maria E; Sierra, Rosa A et al. (2015) l-Arginine depletion blunts antitumor T-cell responses by inducing myeloid-derived suppressor cells. Cancer Res 75:275-83
Dai, Lu; Trillo-Tinoco, Jimena; Bai, Aiping et al. (2015) Ceramides promote apoptosis for virus-infected lymphoma cells through induction of ceramide synthases and viral lytic gene expression. Oncotarget 6:24246-60
Geng, Degui; Kaczanowska, Sabina; Tsai, Alexander et al. (2015) TLR5 Ligand-Secreting T Cells Reshape the Tumor Microenvironment and Enhance Antitumor Activity. Cancer Res 75:1959-1971
Dai, Lu; Chen, Yihan; Bonstaff, Karlie et al. (2015) Induction of hyaluronan production by oncogenic KSHV and the contribution to viral pathogenesis in AIDS patients. Cancer Lett 362:158-66
Dai, Lu; Trillo-Tinoco, Jimena; Cao, Yueyu et al. (2015) Targeting HGF/c-MET induces cell cycle arrest, DNA damage, and apoptosis for primary effusion lymphoma. Blood 126:2821-31
Dai, Lu; Cao, Yueyu; Chen, Yihan et al. (2015) Genomic analysis of xCT-mediated regulatory network: Identification of novel targets against AIDS-associated lymphoma. Oncotarget 6:12710-22

Showing the most recent 10 out of 84 publications